These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30526264)

  • 1. Overnight transdermal scopolamine patch administration has no clear effect on cognition and emotional processing in healthy volunteers.
    Bukala BR; Browning M; Cowen PJ; Harmer CJ; Murphy SE
    J Psychopharmacol; 2019 Feb; 33(2):255-257. PubMed ID: 30526264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans.
    Green A; Ellis KA; Ellis J; Bartholomeusz CF; Ilic S; Croft RJ; Phan KL; Nathan PJ
    Pharmacol Biochem Behav; 2005 Jul; 81(3):575-84. PubMed ID: 15936063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes.
    Mintzer MZ; Griffiths RR
    Exp Clin Psychopharmacol; 2003 Feb; 11(1):56-72. PubMed ID: 12622344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition.
    Johnson CR; Kangas BD; Jutkiewicz EM; Winger G; Bergman J; Coop A; Woods JH
    J Pharmacol Exp Ther; 2021 Jun; 377(3):336-345. PubMed ID: 33712507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice.
    Singh P; Singh TG
    Indian J Pharmacol; 2015; 47(4):388-93. PubMed ID: 26288470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restricted sedation and absence of cognitive impairments after administration of intranasal scopolamine.
    Weerts AP; Pattyn N; Putcha L; Hoag SW; Van Ombergen A; Hallgren E; Van de Heyning PH; Wuyts FL
    J Psychopharmacol; 2015 Dec; 29(12):1231-5. PubMed ID: 26268532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
    Furey ML; Drevets WC
    Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
    Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
    Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estradiol treatment and its interaction with the cholinergic system: effects on cognitive function in healthy young women.
    Bartholomeusz CF; Wesnes KA; Kulkarni J; Vitetta L; Croft RJ; Nathan PJ
    Horm Behav; 2008 Nov; 54(5):684-93. PubMed ID: 18706905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrous cycle stage gates sex differences in prefrontal muscarinic control of fear memory formation.
    Kirry AJ; Durigan DJ; Twining RC; Gilmartin MR
    Neurobiol Learn Mem; 2019 May; 161():26-36. PubMed ID: 30851433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine.
    Baakman AC; Alvarez-Jimenez R; Rissmann R; Klaassen ES; Stevens J; Goulooze SC; den Burger JCG; Swart EL; van Gerven JMA; Groeneveld GJ
    Br J Clin Pharmacol; 2017 Aug; 83(8):1676-1687. PubMed ID: 28217868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caffeine attenuates scopolamine-induced memory impairment in humans.
    Riedel W; Hogervorst E; Leboux R; Verhey F; van Praag H; Jolles J
    Psychopharmacology (Berl); 1995 Nov; 122(2):158-68. PubMed ID: 8848531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of muscarinic receptor blockade-induced impairment of spatial delayed alternation performance by the triazole MDL 26,479.
    Holley LA; Dudchenko P; Sarter M
    Psychopharmacology (Berl); 1992; 109(1-2):223-30. PubMed ID: 1365661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive performance and cholinergic transmission: influence of muscarinic and nicotinic receptor blockade.
    Voss B; Thienel R; Reske M; Habel U; Kircher T
    Eur Arch Psychiatry Clin Neurosci; 2010 Nov; 260 Suppl 2():S106-10. PubMed ID: 20960003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent blockade of beta-adrenergic and muscarinic receptors disrupts working memory but not reference memory in rats.
    Kobayashi M; Ohno M; Yamamoto T; Watanabe S
    Physiol Behav; 1995 Aug; 58(2):307-14. PubMed ID: 7568434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delay-dependent cholinergic modulation of visual short-term memory in rhesus macaques.
    Knakker B; Oláh V; Trunk A; Lendvai B; Lévay G; Hernádi I
    Behav Brain Res; 2021 Jan; 396():112897. PubMed ID: 32891649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of muscarinic and nicotinic receptor antagonists on attention and working memory.
    McQuail JA; Burk JA
    Pharmacol Biochem Behav; 2006 Dec; 85(4):796-803. PubMed ID: 17196638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.
    Renner UD; Oertel R; Kirch W
    Ther Drug Monit; 2005 Oct; 27(5):655-65. PubMed ID: 16175141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.